University of Washington, Seattle, WA, USA.
University of Washington, Seattle, WA, USA.
Cell Host Microbe. 2020 Apr 8;27(4):502-506. doi: 10.1016/j.chom.2020.03.020.
Antiretroviral pre-exposure prophylaxis (PrEP) for the prevention of HIV infection was demonstrated to be efficacious and safe earlier this decade from pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate. Regulatory approval and normative guidance, now for almost 70 countries worldwide, has followed. Demonstration projects have shown high uptake and population-level HIV reductions, highlighting the need for simplifying delivery and reducing current barriers to access and persistence. A portfolio of additional, next-generation PrEP formulations, currently under testing, if effective, will offer users choice and likely increase coverage and impact.
抗逆转录病毒药物事前预防（PrEP）用于预防 HIV 感染，在本世纪初，使用口服恩曲他滨替诺福韦酯的关键性研究证实了其疗效和安全性。此后，监管部门批准了该药物，并发布了规范性指导意见，目前全球近 70 个国家/地区都在使用该药物。示范项目表明，PrEP 的使用率很高，且在人群层面降低了 HIV 的传播，这突出表明需要简化提供方式，并减少当前获取和持续使用的障碍。如果目前正在测试的新一代 PrEP 配方组合有效，将为用户提供更多选择，可能会增加覆盖率并产生更大影响。
